Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3367-3372

  Kuramitsu, Yasuhiro ^a   Taba, Kumiko ^a   Ryozawa, Shomei ^a   Yoshida, Kanako ^a   Zhang, Xiulian ^a   Tanaka, Toshiyuki ^a   Maehara, Shin Ichiro ^b   Maehara, Yoshihiro ^b   Sakaida, Isao ^a   Nakamura, Kazuyuki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Gemcitabine (GEM); LC MS MS; Pancreatic cancer; Proteomics; Two dimensional gel electrophoresis

Indexed keywords

ACIDIC LEUCINE RICH NUCLEAR PHOSPHOPROTEIN 32 FAILY MEMBER A; CATALASE; FAR UPSTREAM ELMENT BINDING PROTEIN 1; FAR UPSTREAM ELMENT BINDING PROTEIN 2; GALECTIN 1; GAMMA SYNUCLEIN; GEMCITABINE; HEAT SHOCK PROTEIN 27; MICROTUBULE ASSOCIATED PROTEIN; NUCLEAR PROTEIN; PEPTIDYLPROLYL ISOMERASE A; RETICULOCALBIN 1; SIALIC ACID SYNTHASE; STATHMIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CANCER RESISTANCE; DOWN REGULATION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; MASS SPECTROMETRY; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEOXYCYTIDINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; PANCREATIC NEOPLASMS; PROTEOMICS; UP-REGULATION;

EID: 77958581453     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Murr MM, Sarr MG, Oishi AJ and van Heerden JA: Pancreatic cancer. CA Cancer J Clin 44: 304-318, 1994.
2. Williamson RC: Pancreatic cancer: the greatest oncological challenge. Br Med J (Clin Res Ed) 13: 445-446, 1988.
3. Gordis L and Gold EB: Epidemiology of pancreatic cancer. World J Surg 8: 808-821, 1984.
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
5. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 1-5, 1996.
6. Bold RJ, Chandra J and McConkey DJ: Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by BCL-2 content. Ann Surg Oncol 6: 279-285, 1999. (Pubitemid 29221014)
7. Shi X, Liu S, Kleeff J, Friess H and Buchler MW: Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62: 354-362, 2002.
8. Cantwell BM, Bozzino JM, Corris P and Harris AL: The multidrug-resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. Eur J Cancer Clin Oncol 24: 123-129, 1988.
9. Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R and Mertelsmann R: Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 49: 630-637, 1991.
10. Togawa A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Shimamura F, Yoshidome H, Katoh A and Miyazaki M: Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-A on the resistant cell line. Pancreas 27: 220-224, 2003.
11. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL and Peters GJ: Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 88: 1963-1970, 2003.
12. Rauchwerger DR, Firby PS, Hedley DW and Moore MJ: Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 60: 6075-6079, 2000.
13. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW and Whang EE: A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 64: 3987-3993, 2004.
14. Maehara S, Tanaka S, Shimada M, Shirabe K, Saito Y, Takahashi K and Maehara Y: Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer 112: 184-189, 2004. (Pubitemid 39244357)
15. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuriya K, Fujimoto M, Maehara S, Maehara Y, Okita K, Nakamura K and Sakaida I: Proteomics finding heat-shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 31: 1345-1350, 2007.
16. Kuramitsu Y, Miyamoto H, Tanaka T, Zhang X, Fujimoto M, Ueda K, Tanaka T, Hamano K and Nakamura K: Proteomic differential display analysis identified up-regulated astrocytic phsphoprotein PEA-15 in human malignant pleural mesothelioma cell lines. Proteomics 9: 5078-5089, 2009.
17. Tanaka T, Kuramitsu Y, Fujimoto M, Naito S, Oka M and Nakamura K: Down-regulation of two isoforms of ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) correlates with high metastatic potentials of human SN12C renal cell carcinoma cell clones. Electrophoresis 29: 2651-2659, 2008.
18. Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Harada T, Fujimoto M, Sakaida I, Okita K, Oka M and Nakamura K: Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics 6: 3894-3900, 2006. (Pubitemid 44065166)
19. Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M and Nakamura K: Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 5: 1686-1692, 2005.
20. Zhang X, Kuramitsu Y, Fujimoto M, Hayashi E, Yuan X and Nakamura K: Proteomic analysis of macrophages stimulated by lipopolysaccharide: Lipopolysaccharide inhibits the cleavage of nucleophosmin. Electrophoresis 27: 1659-1668, 2006.
21. Kuramitsu Y, Harada T, Takashima M, Yokoyama Y, Hidaka I, Iizuka N, Toda T, Fujimoto M, Zhang X, Sakaida I, Okita K, Oka M and Nakamura K: Increased expression, and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues of patients infected with hepatitis C virus. Electrophoresis 27: 1651-1658, 2006.
22. Schafer ZT, Parrish AB, Wright KM, Margolis SS, Marks JR, Deshmukh M and Kornbluth S: Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells. Cancer Res 66: 2210-2218, 2006.
23. Hoffarth S, Zitzer A, Wiewrodt R, Hähnel PS, Beyer V, Kreft A, Biesterfeld S and Schuler M: pp32/PHAPI determines the apoptosis response of non-small cell lung cancer. Cell Death Differ 15: 161-170, 2008.
24. Ozawa M and Muramatsu T: Reticulocalbin, a novel endoplasmic reticulum resident Ca(2+)-binding protein with multiple EFhand motifs and a carboxyl-terminal HDEL sequence. J Biol Chem 268: 699-705, 1993.
25. Tachikui H, Navet AF and Ozawa M: Identification of the Ca(2+)-binding domains in reticulocalbin, an endoplasmic reticulum resident Ca(2+)-binding protein with multiple EF-hand motifs. J Biochem 121: 145-149, 1997.
26. Tong A, Zhang H, Li Z, Gou L, Wang Z, Wei H, Tang M, Liang S, Chen L, Huang C and Wei Y: Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol 61: 791-802, 2008. (Pubitemid 351302035)
27. Morgan J, Hoekstra AV, Chapman-Davis E, Hardt JL, Kim JJ and Buttin BM: Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma. Gynecol Oncol 114: 293-298, 2009.
28. Singh VK, Zhou Y, Marsh JA, Uversky VN, Forman-Kay JD, Liu J and Jia Z: Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs. Cancer Res 67: 626-633, 2007.
29. Zhu D, Cardenas ME and Heitman J: Calcineurin mutants render T lymphocytes resistant to cyclosporin A. Mol Pharmacol 50: 506-511, 1996. (Pubitemid 26303580)
30. Bram RJ, Hung DT, Martin PK, Schreiber SL and Crabtree GR: Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 13: 4760-4769, 1993.
31. Colgan J, Asmal M, Yu B and Luban J: Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. J Immunol 174: 6030-6038, 2005.
32. Wong CS, Wong VW, Chan CM, Ma BB, Hui EP, Wong MC, Lam MY, Au TC, Chan WH, Cheuk W and Chan AT: Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep 20: 89-98, 2008.
33. Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J, Choe W and Kim SS: Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res 67: 3654-3662, 2007.
34. de Vries EG, Meijer C, Timmer-Bosscha H, Berendsen HH, de Leij L, Scheper RJ and Mulder NH: Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res 49: 4175-4178, 1989.
35. Bechtel W and Bauer G: Catalase protects tumor cells from apoptosis induction by intercellular ROS signaling. Anticancer Res 29: 4541-4557, 2009.
36. Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, Schirmacher P and Breuhahn K: Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 50: 1130-1139, 2009.